Amazing Results For Immune Based Treatment of Pancreatic Cancer.

Pancreatic cancer is hard to treat, with survival figures as low as 0.4% at 5 years and survival for metastatic pancreatic cancer remains less than 20% at the end of 1 year. However, a new immune based approach is radically changing the dismal… [Learn More…]

Quizartinib Significantly Increases Survival For AML Patients With FLT3 Mutations

The FLT3-ITD tandem duplication mutation is the most common mutation in AML and this mutation renders the FLT3 enzyme constitutively active, sending a constant growth signal to malignant myeloid cells. The presence of this mutation results in a… [Learn More…]

NOVOCURE TTF UPDATE:

The NovoTTF-100A system is a portable, non-invasive medical device that slows and reverses tumor growth by creating low intensity, alternating electric fields within the tumor. A recent update on the GBM patients from the original pilot study of… [Learn More…]

Anastrozole And Fulvestrant For Post Menopausal, Estrogen Positive Breast Cancer.

  Anastrozole and Fulvestrant are two drugs that are commonly used to treat estrogen (ER) positive breast cancers in postmenopausal patients. Anastrozole works by inhibiting estrogen synthesis while Fulvestrant binds and accelerates… [Learn More…]

Interlaced Chemotherapy For Recurrent High-Grade Gliomas

Many conventional cytotoxic chemotherapies exert their effects during the S or M phase of the cell cycle. One of the major drawbacks of these drugs is that the number of tumor cells destroyed is limited to those cells that happen to be in S or M… [Learn More…]

Lenalidomide For Multiple Myeloma

Lenalidomide is a derivative of the notorious anti-nausea drug Thalidomide, but does not share the same toxicity of Thalidomide. Recent data shows that Lenalidomide maintenance therapy prolongs the time to disease progression after autologous… [Learn More…]

Dacomitinib For EGFR Inhibitor Resistant NSCLC`s

Dacomitinib is one of the latest advances in treatment of EGFR mutant NSCLC’s that have become resistant to reversible EGFR tyrosine kinase inhibitors. Dacomitinib differs from other EGFR inhibitors in that it irreversibly inhibits EGFR, HER2 and… [Learn More…]

GVAX Vaccine for Pancreatic Cancers

GVAX is a vaccine made from pancreatic cancer cells that have been genetically modified to produce the cytokine GM-CSF, which stimulates the immune system. The cells are then irradiated to prevent cell growth. Results from a phase II clinical… [Learn More…]

MRI for Pre-surgical Detection of Mutations in Brain Tumors

Mutations in the isocitrate dehydrogenase genes (IDH1 and IDH2) are found in roughly 70 % of low and intermediate-grade gliomas, and the presence of these mutations means patients generally survive longer, but don’t respond as well to standard… [Learn More…]

Validation of Vemurafenib in Previously Treated BRAF V600 – Mutated Metastatic Melanoma: BRIM 2 Update

Vemurafenib (PLX4032) is a next generation oral BRAF inhibitor for the treatment of metastatic melanoma harbouring the BRAF V600 mutation. Update from the BRIM 2 trial on previously treated patients has shown that 53% of the patients experienced… [Learn More…]